Aphria Offers Big Upside if the Tilray Deal Closes
Aphria offers 90% upside, but this return won’t come for free
Read More»
Locked & Lit: The Grizzle Cannabis Portfolio
See how Grizzle invests in the emerging cannabis industry. Our proprietary portfolio revealed.
Read More»
Why Curaleaf Chairman Boris Jordan is Building Value Not Cashing Out
An interview filled with insights from the chairman of the largest cannabis company in North America
Read More»WITH CHRISTOPHER WOOD
Internationally renowned for his salient predictions of market bubbles, Chris provides global investment insights in his weekly column 'Macro Battleship'.
The Affirm IPO is a Bet on the Future of Peloton
Affirm will run as long as Peloton doesn’t sink it first.
Read More»
Airbnb IPO: Don’t Sleep on This King of Home Rentals
The king of the home rental market is finally going public. How we get to a $500 stock price.
Read More»
C3.ai IPO – Houston We Have a Growth Problem
Is C3.ai the overlooked and undervalued IPO of December?
Read More»
Trulieve CEO Kim Rivers Doesn’t Need Debt to Grow
Kim Rivers talks catalysts, why she doesn’t like debt and where future growth is going to come from in this exclusive interview.
Read More»
Marijuana Investor Roundup: Analysis of the Week’s Most Important Events (Apr 25th, 2020)
A weekly review of only the most important cannabis news to impact your portfolio
Read More»
Organigram Announces $49M At-The-Market Equity Program
As we feared and warned investors about earlier, the company has announced today that it is doing a at-the-market equity raise program valued at $49M.
Read More»
How to Find the Next Wallstreetbets “YOLO” Stock
How you can find the next target of the Wallstreetbets Reddit group before they do.
Read More»
The X for Boys – Teaching Trade Skills to Change Lives
Grizzle is capping off 2020 on a high note, an inspiring interview with King Randall from The X for Boys – changing lives by teaching trade skills.
Read More»
Markets & COVID-19: Dave Collum – Prof. of Organic Chemistry at Cornell
Grizzle interviews Dave Collum, Prof. of Organic Chemistry at Cornell; an engaging chat about markets, gold, covid-19 and all points between.
Read More»PSYCHEDELICS
Why Compass Pathways (CMPS) is a 5-bagger: $210/share
Grizzle outlines the structural share price upside of Compass Pathways and its psilocybin drug: COMP 360 to treat depression.
Read More»
The Most Anticipated Psychedelic IPO: Compass Pathways (CMPS)
Grizzle sits down with Terry Chong (Partner, Grizzle Venture) to discuss one of the most anticipated psychedelic IPOs: Compass Pathaways
Read More»
Grizzle Twitter
AS FEATURED ON
